NCT01497470 - A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

October 31, 2013

Conditions

Cancer

Interventions

DRUG

Custirsen, paclitaxel and carboplatin

Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle

Trial Locations (4)

Unknown

Teva Investigational Site 002, Detroit

Teva Investigational Site 001, Dallas

Teva Investigational Site 003, San Antonio

Teva Investigational Site 004, Tacoma